Intramuscular Vaccine Adjuvants Market

Natural Biodegradables are fastest growing segment fueling the growth of Intramuscular Vaccine Adjuvants Market

by

The global Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Intramuscular vaccine adjuvants are immunostimulants used to boost the immune response against a vaccine. These vaccine adjuvants are combined with specific antigens to help create a stronger, more robust, and longer-lasting immunity. Adjuvants allow for fewer immunizations and decrease the dose of antigen needed.

Market key trends:
One of the key trends in the intramuscular vaccine adjuvants market is the rising focus on developing natural and biodegradable adjuvants. Traditionally, vaccine adjuvants have been aluminum salts which has some limitations including local reactions at injection site and lack of biodegradability. Hence, there is growing emphasis on designing adjuvants from natural sources that have similar immune-stimulating properties but without the adverse effects or environmental issues associated with non-biodegradable compounds. Some examples of emerging natural adjuvants include saponin formulations from Quillaja saponaria tree extract and polysaccharides extracted from fungi and plants. These natural adjuvants have shown potential as alternatives to aluminum adjuvants and are expected to contribute towards the market growth over the forecast period.
Segment Analysis
The Global Intramuscular Vaccine Adjuvants Market is dominated by aluminum-based adjuvants segment. Aluminum salts have been used as adjuvants in vaccines for more than 80 years and due to their efficacy and safety profile, they continue to be the most widely used adjuvants globally. However, newer adjuvant classes like oil-in-water emulsions, liposomes, immunostimulatory complexes (ISCOMs), and oligonucleotides are growing in popularity due to better immunogenicity and less reactogenicity compared to aluminum adjuvants.

Key Takeaways
The global intramuscular vaccine adjuvants market size is expected to reach US$ 1,224.28 Mn by 2030, expanding at a CAGR of 6.7% over the forecast period. Rising prevalence of infectious diseases and increasing vaccination programs worldwide are expected to drive the market.

North America accounted for the largest share of the global market in 2023 and is expected to maintain its dominance over the forecast period. This is attributed to the rising government support towards vaccine development in the region. Asia Pacific is expected to register the fastest growth during the forecast period owing to increasing healthcare expenditure and growing awareness about vaccines in developing countries like India and China.

Key players operating in the intramuscular vaccine adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, and OZ Biosciences. Novavax, Inc. offers a proprietary adjuvant called Matrix-MTM adjuvant with its RSV vaccine candidate to enhance immunogenicity.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it